You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAdenosine
Accession NumberDB00640  (APRD00132)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [PubChem]

Structure
Thumb
Synonyms
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
6-Amino-9-beta-D-ribofuranosyl-9H-purine
9-beta-D-Ribofuranosidoadenine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
Ade-rib
Adenin riboside
Adenine deoxyribonucleoside
Adenocard
Adenocor
Adenoscan
Adenosin
Adenosina
Adénosine
Adenosinum
Adenyldeoxyriboside
Ado
beta-D-Adenosine
Deoxyadenosine
Desoxyadenosine
External Identifiers
  • SR 96225
  • USAF CB-10
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adenocardsolution3 mg/mLintravenousREMEDYREPACK INC.2015-08-19Not applicableUs
Adenocardsolution3 mg/mLintravenousCardinal Health1989-10-30Not applicableUs
Adenocardsolution6 mg/2mLintravenousCardinal Health1989-10-30Not applicableUs
Adenocardsolution3 mg/mLintravenousAstellas Pharma US, Inc.1989-10-30Not applicableUs
Adenocard - Liq Rapid Bolus IV 3mg/mlsolution3 mgintravenousAstellas Pharma Canada Inc1996-08-142014-12-05Canada
Adenocard Injection -pre-filled Syringesolution3 mgintravenousAstellas Pharma Canada Inc1994-12-31Not applicableCanada
Adenocard Liq IV 3mg/mlliquid3 mgintravenousFujisawa Pharmaceutical Co, Division Of Fujisawa Canada Inc.1993-12-311996-09-09Canada
Adenocard Liq IV 3mg/ml (pre-filled Syringe)liquid3 mgintravenousFujisawa Pharmaceutical Co, Division Of Fujisawa Canada Inc.1994-12-311996-09-09Canada
Adenoscansolution3 mg/mLintravenousAstellas Pharma US, Inc.1995-05-18Not applicableUs
Adenoscansolution3 mg/mLintravenousREMEDYREPACK INC.2013-06-10Not applicableUs
Adenoscansolution3 mg/mLintravenousREMEDYREPACK INC.2013-06-27Not applicableUs
Adenoscan - (for IV Infusion Only)solution3 mgintravenousAstellas Pharma Canada Inc1995-12-312009-05-29Canada
Adenosine Injectionsolution3 mgintravenousFresenius Kabi Canada Ltd2007-03-27Not applicableCanada
Adenosine Injection, USPsolution3 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Adenosine Injection, USPsolution3 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Aj-adenosinesolution3 mgintravenousAgila Jamp Canada IncNot applicableNot applicableCanada
Aj-adenosinesolution3 mgintravenousAgila Jamp Canada IncNot applicableNot applicableCanada
PMS-adenosinesolution3 mgintravenousPharmascience Inc2001-06-07Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adenosineinjection3 mg/mLintravenousGeneral Injectables & Vaccines, Inc2014-03-26Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousCardinal Health2011-03-17Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousHospira, Inc.2014-03-24Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousAkorn, Inc.2014-10-02Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousGeneral Injectables & Vaccines, Inc2011-10-05Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousAkorn, Inc.2011-03-15Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousSagent Pharmaceuticals2014-03-28Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousREMEDYREPACK INC.2014-05-23Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousBaxter Healthcare Corporation2010-04-20Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousAGILA SPECIALTIES PRIVATE LIMITED2014-03-22Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousREMEDYREPACK INC.2013-07-16Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousTeva Parenteral Medicines, Inc.2013-09-23Not applicableUs
Adenosineinjection3 mg/mLintravenousWockhardt USA LLC.2009-07-20Not applicableUs
Adenosineinjection3 mg/mLintravenousSagent Pharmaceuticals2009-09-01Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousFresenius Kabi USA, LLC2005-11-23Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousTeva Parenteral Medicines, Inc.2013-09-23Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousHeritage Pharmaceuticals Inc.2014-08-01Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousPhysicians Total Care, Inc.2006-03-16Not applicableUs
Adenosineinjection3 mg/mLintravenousWockhardt Limited2009-07-20Not applicableUs
Adenosineinjection3 mg/mLintravenousWest Ward Pharmaceutical Corp.2004-06-16Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousHeritage Pharmaceuticals Inc.2014-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A.H.c Real Eye for Facecream.12 mg/30mLtopicalCarver Korea Co Ltd2013-06-21Not applicableUs
A.H.C. Collagen Creamcream20 mg/50mLtopicalCarver Korea Co.,Ltd2013-08-15Not applicableUs
A.H.C. Collagen Tonerliquid48 mg/120mLtopicalCarver Korea Co.,Ltd2013-08-15Not applicableUs
Adenosineinjection, solution3 mg/mLintravenousCantrell Drug Company2015-02-05Not applicableUs
Ahc Collagen Serumliquid12 mg/30mLtopicalCarver Korea Co.,Ltd2013-08-15Not applicableUs
Ahc Complex Choice Egf Boostercream.4 mg/mLtopicalCarver Korea Co.,Ltd2013-08-15Not applicableUs
Ahc Complex Choice Egf Boostercream.4 mg/mLtopicalCarver Korea Co.,Ltd2013-08-15Not applicableUs
Ahc Hydration Special Gen Creamcream20 mg/50mLtopicalCarver Korea Co.,Ltd2013-07-15Not applicableUs
Ahc Hydration Special Gen Maskliquid12.8 mg/32gtopicalCarver Korea Co.,Ltd.2013-07-15Not applicableUs
Ahc Hydration Special Gen Serumliquid12 mg/30mLtopicalCarver Korea Co.,Ltd2013-07-15Not applicableUs
Ahc Hydration Special Gen Solutionliquid54 mg/135mLtopicalCarver Korea Co.,Ltd2013-07-15Not applicableUs
Ahc Vital C Complex Maskliquid12 mg/30gtopicalCarver Korea Co.,Ltd2013-08-15Not applicableUs
Aqua Collagen Coenzyme Q10 Hydro Maskpatch.008 g/20gtopicalNature Republic Co., Ltd.2015-02-01Not applicableUs
B.S.c Ampulliquid.6 mg/6mLtopicalCellcos Inc2013-01-30Not applicableUs
Bellaskin Skin-rebirth Contourcream.04 mL/100mLtopicalAjou Medics Co., Ltd2011-09-13Not applicableUs
Capture Hyaluronic Ampouleliquid20 mg/50mLtopicalCarver Korea Co.,Ltd2013-07-05Not applicableUs
Complete Choice Moisture Amplouleliquid6 mg/15mLtopicalCarver Korea Co.,Ltd2013-07-05Not applicableUs
Dr.eslee Triple Action Bbcream.2 g/100gtopicalAjou Medics Co., Ltd2011-09-13Not applicableUs
Elcure Aout Roseliquid.04 mL/100mLtopicalElcure Co., Ltd.2011-08-22Not applicableUs
Elcure Q Serumliquid25 mg/50mLtopicalElcure Co., Ltd.2013-07-18Not applicableUs
Iaso A5 Super Brightening Formulacream.0004 mL/mLtopicalIaso Inc2010-12-21Not applicableUs
Iaso Pregressive Age Care Eyecream.0004 g/gtopicalIaso Inc2011-01-09Not applicableUs
Iaso Progressive Age Carecream.0004 g/gtopicalIaso Inc2011-01-09Not applicableUs
Iaso Progressive Age Care Emulsioncream.0004 mL/mLtopicalIaso Inc2011-01-01Not applicableUs
Iaso Progressive Age Care Serumcream.0004 mL/mLtopicalIaso Inc2011-01-09Not applicableUs
Iaso Progressive Age Care Tonerliquid.0004 mL/mLtopicalIaso Inc2011-01-01Not applicableUs
Iaso Triple Protection Bb SPF 30 Pacream.0004 g/gtopicalIaso Inc2011-01-09Not applicableUs
Mamachi Moms Stretch Mark Creamcream6 g/150gtopicalSupio Co,. Ltd.2014-05-01Not applicableUs
Manefit Beauty Planner Blackberry Firming Eye Maskcream.004 mg/10gtopicalImine Co., Ltd.2016-03-04Not applicableUs
Manefit Beauty Planner Lavender Wrinkle Lifting Maskcream.08 mg/20mLtopicalImine Co., Ltd2014-07-17Not applicableUs
Mioggi Healing Effector Rx Collageniccream.02 mg/50mLtopicalColorpink R&D Inc.2012-08-20Not applicableUs
Mioggi Magic Advanced Skin Essential Activatorliquid.05 mg/125mLtopicalColorpink R&D Inc.2012-08-20Not applicableUs
Niveola 3d Animal Cat Mask Packcream.01 g/27gtopicalUnisource International Co., Ltd.2015-10-08Not applicableUs
Niveola 3d Animal Dog Mask Packcream.01 g/27gtopicalUnisource International Co., Ltd.2015-10-08Not applicableUs
Nmc Magic Serumliquid.04 mg/100mLtopicalNmc (Natural Magma Cosmetics)2013-07-11Not applicableUs
Nmc Staypot Double Programing Creamliquid.04 mg/100mLtopicalNmc (Natural Magma Cosmetics)2013-07-11Not applicableUs
Oozoo Face Ampoule Alpha One Hydro Liftliquid.00012 mg/.3mLtopicalOutin Futures Corp.2016-01-21Not applicableUs
Oozoo Face Ampoule Alpha One Nutrientcream.00012 mg/.3mLtopicalOutin Futures Corp.2016-01-22Not applicableUs
Oozoo Face Mask Alpha One Hydro Liftcream.011 mg/27mLtopicalOutin Futures Corp.2016-01-20Not applicableUs
Oozoo Face Mask Alpha One Illumination Ampoulecream.00012 mg/.3mLtopicalOutin Futures Corp.2016-01-31Not applicableUs
Oozoo Face Mask Alpha One Illumination Maskcream.011 mg/27mLtopicalOutin Futures Corp.2016-01-31Not applicableUs
Oozoo Face Mask Alpha One Illumination Serumcream.001 mg/2.5mLtopicalOutin Futures Corp.2016-01-31Not applicableUs
Oozoo Face Mask Alpha One Nutirientcream.011 mg/27mLtopicalOutin Futures Corp.2016-01-22Not applicableUs
Oozoo Face Serum Alpha One Hydro Liftcream.001 mg/2.5mLtopicalOutin Futures Corp.2016-01-21Not applicableUs
Oozoo Face Serum Alpha One Nutrientcream.001 mg/2.5mLtopicalOutin Futures Corp.2016-01-22Not applicableUs
Primerose Snailcream.0004 1/100mLtopicalRoyal Springs Cosmetics Usa, Llc2015-06-04Not applicableUs
Sallys Box Gold Snail Hydrogel Maskcream.01 g/25gtopicalImine Co., Ltd2015-01-05Not applicableUs
Stem Cell Renewcream.04 mL/mLtopicalMedon Co., Ltd2011-04-06Not applicableUs
Stem Cell Wrinkle Serumliquid.0004 mL/mLtopicalMedon Co., Ltd2011-04-06Not applicableUs
Tosowoong Mens Booster Repairlotion1 mg/150mLtopicalMantong2013-07-05Not applicableUs
U-max Wrinkle Serumliquid.04 mL/100mLtopicalVS Shinbi Co., Ltd.2012-06-04Not applicableUs
International Brands
NameCompany
AdenocorSanofi-Aventis
AdenojectSun
AdenozCelon
AdenozerPurzer
AdesinDae Han New Pharm
AdrekarSanofi-Aventis
AtépadèneMayoly-Spindler
CardimaxAC Farma
CardiovertSanofi-Aventis
KrenosinSanofi-Aventis
OsidenSquare
PisdenoPisa
Brand mixtures
NameLabellerIngredients
Absolute Total Bb Spf37 Pa 3plusWizcoz Corporation Ltd
Ahc Premium Intense Contour BalmCarver Korea Co.,Ltd
Ahc Revitalizing Special Gen CreamCarver Korea Co.,Ltd
Ahc Revitalizing Special Gen MaskCarver Korea Co.,Ltd
Ahc Revitalizing Special Gen SerumCarver Korea Co.,Ltd
Ahc Revitalizing Special Gen SolutionCarver Korea Co.,Ltd
Ahc Vital Complex C-15 AmpouleCarver Korea Co.,Ltd
Birds Nest Forever Young Multi Care LiftingF&Co Co., Ltd.
Capture Collagen AmpouleCarver Korea Co.,Ltd
Conju Princess BbConju Inc
Derma Blemish Balm Blemish BalmUniversal Cosmetic Co., Ltd
Dr Deep Aqua WrinklecreamMineral House Corporation
Dr G Dewrinkle Booster Ample By EgfThe Doctor's Cosmetic Inc
Dr G Dewrinkle Fortifier By EgfThe Doctor's Cosmetic Inc
Dr G Dewrinkle Reformer By EgfThe Doctor's Cosmetic Inc
Galactomyces 95 Whitening Power EssenceCosrx Inc.
Natural Sun AQ Total Anti-aging Essence SunThefaceshop Co., Ltd
Neogen Agecure One Minute Wrinkle RxOutin Futures Corp.
Neogen Code9 Gold Black Caviar EssenceOutin Futures Corp.
Neogen Code9 Lemon Green Caviar EssenceOutin Futures Corp.
P1p Chitosan V-maskPhytos Co., Ltd.
P1p Magic Whitening AntiagingPhytos Co., Ltd.
P1p Skin Rebirth CreamPhytos Co., Ltd.
Plalab Placenta Ample EssenceRenocell Co., Ltd
Plalab Placenta MaskRenocell Co., Ltd
Plalab Placenta R-20Renocell Co., Ltd
Plalab Placenta Skin BoosterRenocell Co., Ltd
Prestige Caviar Full Intensive Vitality TonerFw1 R&D Branch
Prestige Caviar Super Aqua SerumFw1 R&D Branch
Primerose Double Effect EyeRoyal Springs Cosmetics Usa, Llc
Primerose EgfRoyal Springs Cosmetics Usa, Llc
Primerose White Milky CbRoyal Springs Cosmetics Usa, Llc
Rep Nutrinature Ultra All In One MultitemOutin Futures Corp.
Rep Nutrinature Ultra Moist Gel OilOutin Futures Corp.
Rep Nutrinature Ultra Nourishing CreamOutin Futures Corp.
Rep Nutrinature Ultra-all-night Moisture Relief MaskOutin Futures Corp.
Ruby Cell 4uDasan E&T Co., Ltd.
Ruby Cell 4u AmpouleDasan E&T Co., Ltd.
Ruby Cell 4u Ampoule PremiumDasan E&T Co., Ltd.
Sheza Gusl Firming Mask PackPisatap
Skin-ionWako Korea Corp
Snail Skin BoosterNature Republic Co., Ltd.
Super Plus Beblesh Balm Triple Functions Spf50 Plus Pa 3plus (40g)Wizcoz Corporation Ltd
Superplus Beblesh Balm Gold Spf25 Pa 2plusWizcoz Corporation Ltd
Superplus Beblesh Balm Spf25 Pa 2plusWizcoz Corporation Ltd
Superplus Beblesh Balm Triple Functions Spf25 Pa 2plusWizcoz Corporation Ltd
The Oriental Gold Bb Spf25 Pa 2plusWizcoz Corporation Ltd
The Prestige Bb Spf25 Pa 2plusWizcoz Corporation Ltd
SaltsNot Available
Categories
UNIIK72T3FS567
CAS number58-61-7
WeightAverage: 267.2413
Monoisotopic: 267.096753929
Chemical FormulaC10H13N5O4
InChI KeyInChIKey=OIRDTQYFTABQOQ-KQYNXXCUSA-N
InChI
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
IUPAC Name
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
SMILES
NC1=C2N=CN([C@@H]3O[[email protected]](CO)[C@@H](O)[[email protected]]3O)C2=NC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPurine nucleosides
Sub ClassNot Available
Direct ParentPurine nucleosides
Alternative Parents
Substituents
  • Purine ribonucleoside
  • N-glycosyl compound
  • Glycosyl compound
  • 6-aminopurine
  • Purine
  • Imidazopyrimidine
  • Aminopyrimidine
  • Imidolactam
  • Pyrimidine
  • Primary aromatic amine
  • N-substituted imidazole
  • Monosaccharide
  • Saccharide
  • Heteroaromatic compound
  • Oxolane
  • Imidazole
  • Azole
  • Secondary alcohol
  • 1,2-diol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.
PharmacodynamicsAdenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine may exert its pharmacologic effects by activation of purine (cell surface A1 and A2 adenosine) receptors, as well as relax vascular smooth muscles through the reduction in calcium uptake by inhibition of slow inward calcium current and activation of adenylate cyclase in smooth muscle cells. Adenosine may reduce vascular tone by modulation of sympathetic neurotransmission. The drug also has negative chronotropic, dromotropic, and inotropic effects on the heart by slowing conduction time throught he AV node and interrupting AV nodal reentry pathways. Adenosine is a potent vasodilator in most vascular beds, but vasoconstriction is produced in renal afferent arterioles and hepatic veins. The drug produces a net mild to moderate reduction in systolic, diastolic, and mean arterial blood pressure and a reflex increase in heart rate. Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine.
Mechanism of actionAdenosine slows conduction time through the AV node and can interrupt the reentry pathways through the AV node, resulting in the restoration of normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. This effect may be mediated through the drug's activation of cell-surface A1 and A2 adenosine receptors. Adenosine also inhibits the slow inward calcium current and activation of adenylate cyclase in smooth muscle cells, thereby causing relaxation of vascular smooth muscle. By increasing blood flow in normal coronary arteries with little or no increase in stenotic arteries (with little to no increase in stenotic arteries), adenosine produces a relative difference in thallous (thallium) chloride TI 201 uptake in myocardium supplied by normal verus stenotic coronary arteries.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol.

SubstrateEnzymesProduct
Adenosine
Not Available
Adenosine monophosphateDetails
Adenosine
Not Available
InosineDetails
Route of eliminationNot Available
Half lifeLess than 10 secs
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Myoadenylate deaminase deficiencyDiseaseSMP00537
Betaine MetabolismMetabolicSMP00123
Cystathionine Beta-Synthase DeficiencyDiseaseSMP00177
Intracellular Signalling Through Adenosine Receptor A2a and AdenosineSignalingSMP00320
Gout or Kelley-Seegmiller SyndromeDiseaseSMP00365
Azathioprine Action PathwayDrug actionSMP00427
Xanthinuria type IIDiseaseSMP00513
AICA-RibosiduriaDiseaseSMP00168
Mercaptopurine Action PathwayDrug actionSMP00428
Thioguanine Action PathwayDrug actionSMP00430
Xanthinuria type IDiseaseSMP00512
Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation typeDiseaseSMP00570
Adenylosuccinate Lyase DeficiencyDiseaseSMP00167
Molybdenum Cofactor DeficiencyDiseaseSMP00203
Purine Nucleoside Phosphorylase DeficiencyDiseaseSMP00210
S-Adenosylhomocysteine (SAH) Hydrolase DeficiencyDiseaseSMP00214
Glycine N-methyltransferase DeficiencyDiseaseSMP00222
Intracellular Signalling Through Adenosine Receptor A2b and AdenosineSignalingSMP00321
Adenine phosphoribosyltransferase deficiency (APRT)DiseaseSMP00535
Mitochondrial DNA depletion syndromeDiseaseSMP00536
Selenoamino Acid MetabolismMetabolicSMP00029
Methionine MetabolismMetabolicSMP00033
Purine MetabolismMetabolicSMP00050
Adenosine Deaminase DeficiencyDiseaseSMP00144
Xanthine Dehydrogenase Deficiency (Xanthinuria)DiseaseSMP00220
Methionine Adenosyltransferase DeficiencyDiseaseSMP00221
HypermethioninemiaDiseaseSMP00341
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9227
Blood Brain Barrier+0.9383
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.7026
P-glycoprotein inhibitor INon-inhibitor0.966
P-glycoprotein inhibitor IINon-inhibitor0.9533
Renal organic cation transporterNon-inhibitor0.9444
CYP450 2C9 substrateNon-substrate0.8639
CYP450 2D6 substrateNon-substrate0.8349
CYP450 3A4 substrateNon-substrate0.5866
CYP450 1A2 substrateNon-inhibitor0.9667
CYP450 2C9 inhibitorNon-inhibitor0.9595
CYP450 2D6 inhibitorNon-inhibitor0.977
CYP450 2C19 inhibitorNon-inhibitor0.9514
CYP450 3A4 inhibitorNon-inhibitor0.962
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9701
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable0.9738
Rat acute toxicity1.9715 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.989
hERG inhibition (predictor II)Non-inhibitor0.9102
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astellas pharma us inc
  • Akorn inc
  • App pharmaceuticals llc
  • Baxter healthcare corp
  • Bedford laboratories div ben venue laboratories inc
  • Gland pharma ltd
  • Luitpold pharmaceuticals inc
  • Strides arcolab ltd
  • Teva parenteral medicines inc
  • Wockhardt ltd
Packagers
Dosage forms
FormRouteStrength
Creamtopical.12 mg/30mL
Liquidtopical48 mg/120mL
Solutionintravenous6 mg/2mL
Solutionintravenous3 mg
Liquidintravenous3 mg
Solutionintravenous3 mg/mL
Injectionintravenous3 mg/mL
Injection, solutionintravenous3 mg/mL
Creamtopical.4 mg/mL
Creamtopical20 mg/50mL
Liquidtopical12.8 mg/32g
Liquidtopical12 mg/30mL
Liquidtopical54 mg/135mL
Liquidtopical
Liquidtopical12 mg/30g
Patchtopical.008 g/20g
Liquidtopical.6 mg/6mL
Creamtopical.04 mL/100mL
Liquidtopical20 mg/50mL
Liquidtopical6 mg/15mL
Solution/ dropstopical
Creamtopical
Creamtopical.2 g/100g
Liquidtopical25 mg/50mL
Creamtopical.0004 mL/mL
Liquidtopical.0004 mL/mL
Creamtopical.0004 g/g
Creamtopical6 g/150g
Creamtopical.004 mg/10g
Creamtopical.08 mg/20mL
Creamtopical.02 mg/50mL
Liquidtopical.05 mg/125mL
Creamtopical.01 g/27g
Liquidtopical.04 mg/100mL
Liquidtopical.00012 mg/.3mL
Creamtopical.00012 mg/.3mL
Creamtopical.011 mg/27mL
Creamtopical.001 mg/2.5mL
Patchtopical
Creamtopical.0004 1/100mL
Oiltopical
Solutiontopical
Creamtopical.01 g/25g
Spraytopical
Creamtopical.04 mL/mL
Lotiontopical1 mg/150mL
Liquidtopical.04 mL/100mL
Prices
Unit descriptionCostUnit
Adenosine-5 monophosphate19.74USD g
Adenosine powder15.86USD g
Adenoscan 3 mg/ml vial10.09USD ml
Adenosine 12 mg/4 ml vial8.44USD ml
Adenosine 6 mg/2 ml vial8.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5731296 No1995-03-242015-03-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point235.5 °CPhysProp
water solubility8230 mg/LNot Available
logP-1.05HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility14.0 mg/mLALOGPS
logP-1.2ALOGPS
logP-2.1ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)4.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area139.54 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity63.2 m3·mol-1ChemAxon
Polarizability25.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.12 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-0f7w-1890000000-5c70a5423faa5e8eceafView in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-001v-0691000000-8f88854b7d5adec5c558View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-001s-0790000000-cc3bcd977e11efd4ea25View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS)splash10-00di-9460000000-3ae19bfaa5d2df72f9b1View in MoNA
GC-MSGC-MS Spectrum - GC-MS (3 TMS)splash10-0gc0-0590000000-05874cecded3009c1f4dView in MoNA
GC-MSGC-MS Spectrum - GC-MS (4 TMS)splash10-0fsv-1792000000-b37fd6826f28aaf9e825View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-014r-0890000000-588861a9494ab4680698View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-000i-1900000000-dd7cbed8e76c6e783831View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-000i-2900000000-c6644520b5943b59403dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-014i-0090000000-3d4fd8ea211eaed10531View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-000i-0900000000-cb58ec56a5faa09c9a02View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-000i-0900000000-9559aa07ec13a688fb16View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Positivesplash10-000i-0900000000-f7c1371d8e1058df3a32View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-001i-0940000000-da71247788bf1ba222e2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-001i-0920000000-f2e8ec028abdd674b5e3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-001i-0910000000-815ed65588c07415cd65View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-001i-1910000000-2780e737da8848411c4fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-053r-1900000000-c6c1128990661334c15bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-014i-0090000000-106e7131507fadd4befbView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-000i-0910000000-1c53823486cd2c23f90eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-000i-0900000000-f0313435db4847490fd6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-000i-1900000000-dcd4c2972882dcd7535aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-000i-2900000000-5ee474864189cef6df64View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-000i-0900000000-17edf36faf6eb5750912View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-000i-0900000000-0591143763a0bad31c23View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-014i-0290000000-f1d71a97ce39145c8e31View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, Positivesplash10-00kr-0950000000-9bbdbb14aed287ad5ac8View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negativesplash10-001i-0910000000-35f90965f1f3c2b3236bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positivesplash10-000i-0900000000-f360cca994696d7ae735View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,1H] 2D NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Giorgio Stramentinoli, Federico Gennari, “Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity.” U.S. Patent US4373097, issued October, 1965.

US4373097
General ReferencesNot Available
External Links
ATC CodesC01EB10
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (154 KB)
MSDSDownload (72.7 KB)
Interactions
Drug Interactions
Drug
AminophyllineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline.
CaffeineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine.
DigoxinThe risk or severity of adverse effects can be increased when Digoxin is combined with Adenosine.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Adenosine.
DyphyllineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Dyphylline.
NicotineNicotine may increase the atrioventricular blocking (AV block) activities of Adenosine.
TheophyllineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline.
Food Interactions
  • Avoid caffeine containing foods and drinks.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Identical protein binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2A
Uniprot ID:
P29274
Molecular Weight:
44706.925 Da
References
  1. Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662 ]
  2. Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661 ]
  3. Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471 ]
  4. Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9. [PubMed:16339914 ]
  5. Kreckler LM, Gizewski E, Wan TC, Auchampach JA: Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. J Pharmacol Exp Ther. 2009 Dec;331(3):1051-61. doi: 10.1124/jpet.109.157651. Epub 2009 Sep 11. [PubMed:19749080 ]
  6. Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829 ]
  7. Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146 ]
  8. Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled adenosine receptor activity
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
ADORA2B
Uniprot ID:
P29275
Molecular Weight:
36332.655 Da
References
  1. Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662 ]
  2. Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661 ]
  3. Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471 ]
  4. Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9. [PubMed:16339914 ]
  5. Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829 ]
  6. Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146 ]
  7. Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled adenosine receptor activity
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.
Gene Name:
ADORA3
Uniprot ID:
P0DMS8
Molecular Weight:
36184.175 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662 ]
  3. Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661 ]
  4. Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471 ]
  5. Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9. [PubMed:16339914 ]
  6. Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829 ]
  7. Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146 ]
  8. Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Purine nucleoside binding
Specific Function:
Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
ADORA1
Uniprot ID:
P30542
Molecular Weight:
36511.325 Da
References
  1. Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning. Curr Top Med Chem. 2010;10(9):860-77. [PubMed:20370662 ]
  2. Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends. Curr Top Med Chem. 2010;10(9):878-901. [PubMed:20370661 ]
  3. Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29. [PubMed:17321471 ]
  4. Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. doi: 10.1111/j.1476-5381.2009.00614.x. Epub 2010 Feb 5. [PubMed:20136829 ]
  5. Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16. [PubMed:17438146 ]
  6. Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9. [PubMed:17442976 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
Gene Name:
ADA
Uniprot ID:
P00813
Molecular Weight:
40764.13 Da
References
  1. Kopff M, Kopff A, Puczkowski S: [Adenosine deaminase: isoenzymes ADA1 and ADA2]. Pol Merkur Lekarski. 1997 Dec;3(18):288-90. [PubMed:9523470 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Poly(a) rna binding
Specific Function:
ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides.
Gene Name:
ADK
Uniprot ID:
P55263
Molecular Weight:
40545.075 Da
References
  1. Boison D: Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci. 2006 Dec;27(12):652-8. Epub 2006 Oct 23. [PubMed:17056128 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Pyrimidine- and adenine-specific:sodium symporter activity
Specific Function:
Sodium-dependent, pyrimidine- and purine-selective. Involved in the homeostasis of endogenous nucleosides. Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtype (N3/cib) (with marked transport of both thymidine and inosine). Employs a 2:1 sodium/nucleoside ratio. Also able to transport gemcitabine, 3'-azido-3'-deoxythymidine (AZT), ribavirin and 3-deazaurid...
Gene Name:
SLC28A3
Uniprot ID:
Q9HAS3
Molecular Weight:
76929.61 Da
References
  1. Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM: Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005;5(3):157-65. [PubMed:15738947 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11